Related Experiment Video
Updated: May 10, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Beta-blockers for preventing stroke recurrence
Luiz Gustavo De Lima1, Bernardo G O Soares, Humberto Saconato
1Brazilian Cochrane Centre, Universidade Federal de São Paulo, São Paulo, Brazil.
The Cochrane Database of Systematic Reviews
|June 4, 2013
Summary
Beta-blockers do not currently show evidence for preventing stroke recurrence or reducing vascular events in patients with a history of stroke or TIA. Further research with larger sample sizes is required to confirm these findings.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke impacts 15 million individuals globally each year, emphasizing the critical need for effective secondary prevention strategies.
- Recurrence rates for stroke are high, necessitating ongoing research into interventions beyond acute treatment.
- Beta-blockers are being investigated for their potential role in stroke secondary prevention due to their known effects beyond blood pressure reduction.
Purpose of the Study:
- To assess the efficacy of beta-blockers in preventing stroke recurrence and reducing mortality and major vascular events in individuals with a prior stroke or TIA.
- To evaluate the safety profile of beta-blockers, with a specific focus on their potential to induce diabetes mellitus.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
- Searches were performed across multiple databases including Cochrane, MEDLINE, and EMBASE up to December 2011.
- Two RCTs involving 2193 participants comparing beta-blockers (atenolol) to placebo were included.
Main Results:
- No statistically significant differences were observed in the risk of fatal or non-fatal stroke between the beta-blocker and placebo groups (RR 0.94, 95% CI 0.75 to 1.17).
- Analysis of other outcomes, including all-cause mortality, cardiac death, non-fatal myocardial infarction, and major vascular events, revealed no significant differences between the treatment groups.
- The safety data regarding the development of diabetes mellitus was not explicitly detailed in the main results but was part of the study's objective.
Conclusions:
- Current evidence does not support the routine use of beta-blockers for secondary prevention following stroke or TIA.
- Larger-scale studies with increased participant numbers are necessary to definitively establish the role, if any, of beta-blockers in stroke secondary prevention.
- The findings suggest that other therapeutic strategies should be prioritized for secondary stroke prevention at this time.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...